Business Of Biotech cover image

Modernizing Clinical Trial Operations With Merck's Jennifer Sheller

Business Of Biotech

00:00

Using ICH GCP and risk proportionality (R3)

Sheller explains ICH GCP revision three emphasizes risk-based approaches and focusing rigor on critical data.

Play episode from 33:38
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app